BIO

Name: BIO
Brand: Selleck Chemicals
SKU: S7198
Rating: 5 (19 reviews)

For research use only.

Catalog No.S7198 Synonyms: GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052

19 publications

CAS No. 667463-62-9

BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.

Selleck's BIO has been cited by 19 publications

Cell Stem Cell, 2020, S1934-5909(20)30541-5

PubMed: 33271070 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00303-2

PubMed: 34216546 ( click the link to review the publication )

J Ethnopharmacol, 2021, 280:114449

PubMed: 34332067 ( click the link to review the publication )

Biomedicines, 2021, 9(8)949

PubMed: 34440153 ( click the link to review the publication )

Stem Cells, 2020, 10.1002/stem.3274

PubMed: 32930441 ( click the link to review the publication )

Front Immunol, 2020, 27;11:438

PubMed: 32292402 ( click the link to review the publication )

Carcinogenesis, 2020, 41(7):993-1004

PubMed: 31740922 ( click the link to review the publication )

Clin Cancer Res, 2019, 1;25(21):6452-6462

PubMed: 31533931 ( click the link to review the publication )

Cancer Lett, 2019, 463:11-26

PubMed: 31404613 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(9):6521-6538

PubMed: 30852795 ( click the link to review the publication )

Stem Cells Dev, 2019, 10.1089/scd.2019.0011

PubMed: 31062657 ( click the link to review the publication )

Mol Med Rep, 2019, 20(1):33-40

PubMed: 31115502 ( click the link to review the publication )

Mol Cell, 2018, 72(1):37-47

PubMed: 30197296 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5154

PubMed: 30514931 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Int J Oncol, 2017, 50(1):101-110

PubMed: 27909720 ( click the link to review the publication )

Stem Cell Res, 2017, 23:182-187

PubMed: 28772167 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2432

PubMed: 27787516 ( click the link to review the publication )

PLoS One, 2014, 9(7):e100947

PubMed: 24984063 ( click the link to review the publication )

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Description

Features

The first pharmacological agent shown to maintain self-renewal in human and mouse embryonic stem cells.

Targets

GSK-3 ^[1] (Cell-free assay)	TYK2 ^[4] (Cell-free assay)	CDK5/p35 ^[1] (Cell-free assay)	CDK2/CyclinA ^[1] (Cell-free assay)	CDK1/CyclinB ^[1] (Cell-free assay)	View More
5 nM	30 nM	0.08 μM	0.30 μM	0.32 μM	View More

In vitro

BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of glycogen synthase kinase-3 (GSK-3), with IC50 of 5 nM for GSK-3α/β, shows >16-fold selectivity over CDK5. BIO interacts within the ATP binding pocket of these kinases, reduces β-catenin phosphorylation on a GSK-3-specific site in cellular models, closely mimicks Wnt signaling in Xenopus embryos. ^[1] In human and mouse embryonic stem cells, BIO maintains the undifferentiated phenotype and sustains expression of the pluripotent state-specific transcription factors Oct-3/4, Rex-1 and Nanog. BIO-mediated Wnt activation is functionally reversible, as withdrawal of the compound leads to normal multidifferentiation programs in both human and mouse embryonic stem cells. ^[2] BIO promotes proliferation in mammalian cardiomyocytes. ^[3]6BIO is also a pan-JAK inhibitor, with IC50 values of 0.03, 1.5, 8.0, 0.5 μM for TYK2, JAK1, JAK2 and JAK3. BIO selectively inhibits phosphorylation of STAT3 and induces apoptosis of human melanoma cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HEI-OC1	MlvwSpVv[3Srb36gZZN{[Xl?			MnvIVJJwfGWldHnvckBi\2GrboP0JINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIghcW5ibnXvcoF1[WxibX;1d4UhUEWLLV;DNUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3HzdIF{\S1\|L{egZYN1cX[rdImsJGVEPTBiPTCwMlE6OiEQvF2u	MlqxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByOUG5NVUoRjNyMEmxPVE2RC:jPh?=
SH-SY5Y	NHKzb2lHfW6ldHnvckBie3OjeR?=			MUnJcohq[mm2aX;uJI9nKEeVS{OtcYVlcWG2ZXSgZoV1[S2lYYPlbY4heGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHNJNVO\NWmgZ4VtdHNiaX6gdJJme2WwY3Wgc4YhVUdzM{KgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|LDDJR\|UxKD1iMD6yPUDPxE1w	MlPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MU[xNVAoRjF6OEG2NVExRC:jPh?=
K562	MoXmRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYnHXWZuPzJiaILz	NYD4cFVqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxMlMh\|ryPLh?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd6M{G0PUc,OTl5OEOxOFk9N2F-
IMR90	M{LkUGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYq5fYRpPzJiaILz	Ml:4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCLTWK5NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMT65JO69VS5?	M{HrTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{izNVQ6Lz5zOUe4N\|E1QTxxYU6=
HCT116	MmLERY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{HSflczKGi{cx?=	MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNT6yJO69VS5?	MkPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5OEOxOFkoRjF7N{izNVQ6RC:jPh?=
HepG2	NWm0PIw2S3m2b4TvfIlkcXS7IHHzd4F6		NEnZNXIzPCCqcoO=	NHLCOZBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFI1KGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFUvOyEQvF2u	M2rHUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{SzOFkzLz5{OEe0N\|Q6OjxxYU6=
HL60	M{mwZ2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3LFdlUh\GG7cx?=	Mlr5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTE[wJINmdGy\|IHHmeIVzKDViZHH5d{BjgSCPVGSgZZN{[XluIFnDOVAhRSB3LkSg{txONg>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd6M{G0PUc,OTl5OEOxOFk9N2F-
HuH7	NXznW4RQSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXi3NkBpenN?	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEi3SEegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDZwMjFOwG0v	M3:zNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{izNVQ6Lz5zOUe4N\|E1QTxxYU6=
SH-SY5Y	NYm4SG5ZS3m2b4TvfIlkcXS7IHHzd4F6		M{\RTFQ5KGi{cx?=	MnrHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2guW1l3WTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSVIILl[JVkfGmxbjDhd5NigSxiSVO1NEA:KDlizszNMi=>	NFTRWFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEixOlEyOCd-MUi4NVYyOTB:L3G+
SH-SY5Y	M4fI[2Z2dmO2aX;uJIF{e2G7		NInyUmI1QCCqcoO=	MVPTeZJ3cX[jbDDv[kBpfW2jbjDTTE1UYTW\IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFNicnXkeYN1cW:wIHHzd4F6NCCLQ{WwJF0hQS53IN88UU4>	NInWd5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNki1OFA3QSd-MU[4OVQxPjl:L3G+
SH-SY5Y	NXjKXlVxTnWwY4Tpc44h[XO\|YYm=			Ml65SIVifGhib3[gbJVu[W5iU1itV3k2YSClZXzsd{BqdiCjYoPlcoNmKG:oIEKwJJVOKFFvVlStU3BpKGK7IF3UV{Bz\WS3Y4Tpc44h[XO\|YYmsJGlEPTBiPTCxNEDPxE1w	NEW2NJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNki1OFA3QSd-MU[4OVQxPjl:L3G+
SH-SY5Y	M3nkdmZ2dmO2aX;uJIF{e2G7			MnX5SIVifGhib3[gbJVu[W5iU1itV3k2YSClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEB2VSCTLW\EMW9RcCCkeTDNWHMhemWmdXP0bY9vKGG\|c3H5MEBKSzVyIE2gNVMh\|ryPLh?=	M2Lub\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEW0NFY6Lz5zNki1OFA3QTxxYU6=
SH-SY5Y	M4fDXWZ2dmO2aX;uJIF{e2G7		NVrxZ\|JQOjRiaILz	NWnJZ5R7W3W{dnn2ZYwhd2ZiaIXtZY4hW0hvU2m1XUBk\WyuczDh[pRmeiB{NDDodpMh[nliTWTTJJJm\HWldHnvckBie3OjeTygTWM2OCB;IEG4JO69VS5?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjh3NEC2PUc,OTZ6NUSwOlk9N2F-
IMR32	M4rZVGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2DTUFQ5KGi{cx?=	MnnDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTW1TOzJiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfS=>	NGG1OpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwNlk1Pyd-MkG4NFI6PDd:L3G+
SK-N-SH	M3W0NmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NYjyUGVvPDhiaILz	NUTrZXVjS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTj3TTEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyMkm0O{c,OjF6MEK5OFc9N2F-
NB39	MmfxR5l1d3SxeHnjbZR6KGG\|c3H5		Moj6OFghcHK\|	MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDORlM6KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYm=	M2jSOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOECyPVQ4Lz5{MUiwNlk1PzxxYU6=
A673	M1XTfpFJXFNiYYPzZZk>			NILZUIVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	MnXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	MXTxTHRUKGG\|c3H5			Mmf4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	MoTUdWhVWyCjc4PhfS=>			NXP2UWdoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NXfMfZVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NGLoUJhyUFSVIHHzd4F6			M3nhPZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	M4\FZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	NVvjdnBVeUiWUzDhd5NigQ>?			NFXTUZNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	NUX0VlNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	MnjrdWhVWyCjc4PhfS=>			MoDjdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	NIrEWHVyUFSVIHHzd4F6			M3LKNJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	NY\n[nlLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NYLTb4NqeUiWUzDhd5NigQ>?			M1G2RZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	M1LBbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	M4P5ZZFJXFNiYYPzZZk>			M3zpU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	M{nzdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	MmnldWhVWyCjc4PhfS=>			M1jpO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	NGHKVlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NID4fmtyUFSVIHHzd4F6			M1yxe5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	MYjxTHRUKGG\|c3H5			NVzkO\|VyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoN\|Ah[2WubIO=	Ml;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MljNdWhVWyCjc4PhfS=>			NU[zXFNLeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NGe0T2tyUFSVIHHzd4F6			MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NFS5N289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	NXPJO\|A1eUiWUzDhd5NigQ>?			MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	NIXZblI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	M2fmOZFJXFNiYYPzZZk>			NIjH[VhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	NYDPUWFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	Mn3jdWhVWyCjc4PhfS=>			NXHSeok2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	MmHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A549	NFHnbFJHfW6ldHnvckBie3OjeR?=	NHz4OVcyOCC3TR?=	M3TNSlE2KG2rboO=	NX72NVRRUW6qaXLpeIlwdiCxZjDoeY1idiCvUFfFV\|Eh\nKxbTDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJHBITTJiYYSgNVAhfU1iYX\0[ZIhOTVibXnud{BjgSCKUFzD	MoLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OUeyOFQoRjJ2Nkm3NlQ1RC:jPh?=
HEK293	NYrHV3pzTnWwY4Tpc44h[XO\|YYm=	M{fUV\|AvPSC2bzCxJJVO		M4\5b2lvcGmkaYTpc44hd2ZiaIXtZY4hT1ONMzDhZ5Rqfmm2eTDpckBJTUt{OUOgZ4VtdHNiY3;ueIFqdmmwZzD0bIUhX262L3LleIEu[2G2ZX7pckBi[3SrdnH0[YQhemWyb4L0[ZIheFO3cHXyWG9RTkyDU1igLHNVTjJ7MzDj[YxteyliYYSgNE42KHSxIEGgeW0h[nliV370JJJmeG:{dHXyJIdmdmViYYPzZZk>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ7N{K0OEc,OjR4OUeyOFQ9N2F-
sf9	Mom0SpVv[3Srb36gZZN{[Xl?	MoraNUB2VQ>?		M{HrfmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGNFUzRiKGO0JJRwKEV\|MEOgdoV{cWS3ZYOpM2N6[2yrbjDENUApWTRidH:gTVI6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{BifCBzIIXNJJV{cW6pIGLCMWNVTiCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl?	NGTQe\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O\|Q{OCd-Mki1OVc1OzB:L3G+
sf9	MXXGeY5kfGmxbjDhd5NigQ>?	NIjvV3kyKHWP		MX7Jcohq[mm2aX;uJI9nKGi3bXHuJG4ufGW{bXnuZYwhT1OWL1jpd\|YufGGpZ3XkJGdUUzOkZYThJEhOOSC2bzDUOFIxKHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z7IHPlcIx{KGG2IEGgeW0hfXOrbnegVmJGWi2LUmP0bYRmKGG\|IIP1ZpN1emG2ZTDifUBncWy2ZYKgZolv\GmwZzDhd5NigQ>?	MlH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N\|AoRjJ6NUW3OFMxRC:jPh?=
sf9	MWrGeY5kfGmxbjDhd5NigQ>?	MXKxJJVO		MXzJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDDSGszKCiPMTD0c{BNOjl6IILld4llfWW\|KT;DfYNtcW5iQUKgLG0yKHSxIFy0N\|IhemW\|aXT1[ZMqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EB{\jliY3XscJMh[XRiMTD1UUB2e2mwZzDIbZN1d26nIFixJIF{KHO3YoP0doF1\SCkeTDmbYx1\XJiYnnu[Ilv\yCjc4PhfS=>	MnLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N\|AoRjJ6NUW3OFMxRC:jPh?=
sf9	NVv2dXM1TnWwY4Tpc44h[XO\|YYm=	NYi3RmVTOSC3TR?=		MnXLTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgR2RMPSBqTUGgeI8hWDJ7MjDy[ZNq\HWnczmvdFM2VkONIDjNNUB1dyCUM{C3JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgd4Y6KGOnbHzzJIF1KDFidV2geZNqdmdiUlKtR3RHKGG\|IIP1ZpN1emG2ZTDifUBncWy2ZYKgZolv\GmwZzDhd5NigQ>?	NHjmdXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O\|Q{OCd-Mki1OVc1OzB:L3G+
sf9	NHr0cIFHfW6ldHnvckBie3OjeR?=	NVTzU2ZQOSC3TR?=		NYC4ToU3UW6qaXLpeIlwdiCxZjDoeY1idiCQLYTldo1qdmGuIFfTWE9JcXN4LYTh[4dm\CCDdYLvdoEhSiBqQUKgeI8hSTN2NDDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKHOoOTDj[YxteyCjdDCxJJVOKHW\|aX7nJJRmfHKjKFzSVmxUVEdrIHHzJJN2[nO2cnH0[UBjgSCoaXz0[ZIh[mmwZHnu[{Bie3OjeR?=	NX24N2xyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9	MYnGeY5kfGmxbjDhd5NigQ>?	NGjY[WEyKHWP		NX7DSY14UW6qaXLpeIlwdiCxZjDoeY1idiCQLYTldo1qdmGuIFfTWE9JcXN4LYTh[4dm\CCIR1\SNUApTzRyMDD0c{BTQDJyIILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JINmdGy\|IHH0JFEhfU1idYPpcochWG:ueTjHcJUtXHm{KUS6NUBieyC\|dXLzeJJifGViYomg[oltfGW{IHLpcoRqdmdiYYPzZZk>	NIXwUGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O\|Q{OCd-Mki1OVc1OzB:L3G+
sf9	M2LpOGZ2dmO2aX;uJIF{e2G7	MkjsNUB2VQ>?		MVHJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUM2hqezZvdHHn[4VlKEOGS{GgLG0yKHSxIF2yPVchemW\|aXT1[ZMqN0O7Y3zpckBDOSBqTUGgeI8hXjR\|MzDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKHOoOTDj[YxteyCjdDCxJJVOKHW\|aX7nJHJDNUOWRjDhd{B{fWK\|dILheIUh[nliZnnseIVzKGKrbnTpcoch[XO\|YYm=	NXzvOJlHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9	NIKyNFdHfW6ldHnvckBie3OjeR?=	NV74PZlKOSC3TR?=		NG\LTppKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBETEt{IDjNNUB1dyCOMkm4JJJme2mmdXXzLU9EgWOuaX6gSVEhME1zIITvJGE{QTVicnXzbYR2\XNrIHX4dJJme3OnZDDpckB{\jliY3XscJMh[XRiMTD1UUB2e2mwZzDSRk1EXEZiYYOgd5Vje3S{YYTlJIJ6KG[rbITldkBjcW6maX7nJIF{e2G7	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N\|A9N2F-
sf9	MWTGeY5kfGmxbjDhd5NigQ>?	MW[xJJVO		NH6xeo5KdmirYnn0bY9vKG:oIHj1cYFvKE5vdHXycYlv[WxiR2PUM2hqezZvdHHn[4VlKEG3cn;yZUBCKCiPMTD0c{BUPDB\|IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JINmdGy\|IHH0JFEhfU1idYPpcochfGW2cnGoUHJTVFOORzmgZZMhe3Wkc4TyZZRmKGK7IH\pcJRmeiCkaX7kbY5oKGG\|c3H5	Ml;KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N\|AoRjJ6NUW3OFMxRC:jPh?=
sf9	NEnOUW5HfW6ldHnvckBie3OjeR?=	MonmNUB2VQ>?		MnTBTY5pcWKrdHnvckBw\iCqdX3hckBPNXSncn3pcoFtKEeVVD30ZYdo\WRiQYXyc5JiKEJiKF2xJJRwKFN{NzDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKHOoOTDj[YxteyCjdDCxJJVOKHW\|aX7nJGNFSzJ3Qz3k[ZJqfmWmIIDldJRq\GViYYOgd5Vje3S{YYTlJIJ6KG[rbITldkBjcW6maX7nJIF{e2G7	Mmm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N\|AoRjJ6NUW3OFMxRC:jPh?=
HT22	NXrZVYtTTnWwY4Tpc44h[XO\|YYm=	M2OxVFExKHWP	M4jSSlI1KGi{cx?=	NHTDR5pKdmirYnn0bY9vKG:oIFfTT\|MudWWmaXH0[YQh[mW2YTDjZZNmcW5icHjvd5Bpd3K7bHH0bY9vKGmwIH3veZNmKEiWMkKgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrczDpckBxemW\|ZX7j[UBw\iCPR{GzNi=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl7OES0N{c,OjJ7OUi0OFM9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p21 / p27 ; PubMed: 27510556 Sci Rep In BIO treatment of cardiac fibroblasts for 1 day, the protein levels of phosphorylated Akt, p21, and p27 were assessed. p-β-catenin / β-catenin ; PubMed: 27211495 Sci Rep ERKi and GSK3i differently regulate PI3K/Akt and β-catenin pathways. U0126 increased while BIO decreased Akt phosphorylation after 24 hours of treatment. BIO prevented β-catenin phosphorylation leading to intact β-catenin accumulation, while U0126 only had a marginal effect. FoxO3a / FoxO1 / p-FoxO3a / p-FoxO1 ; PubMed: 27211495 Sci Rep U0126 markedly increased the phosphorylation of Akt downstream targets FOXO1 and FOXO3a, while BIO decreased it.	27510556 27211495
Immunofluorescence	pAKT / p21 / p27 ; PubMed: 27510556 Sci Rep Protein expressions of pAkt, p21 and p27 were determined by immunofluorescence staining in cardiac fibroblasts treated with BIO for 1 day. *p < 0.05, t-test. Scale bar = 100 μm. TNF-α; PubMed: 24286133 Arthritis Res Ther Detection of TNF-α protein expression by immunofluorescence microscopy. Nucleus pulposus cells were cultured with or without 1.0 μM BIO for 24 h, fixed, and stained with an antibody against c-fos. Left: cells stained with an antibody to TNF-α; middle: cells stained with 4′,6-diamidino-2-phenylindole (DAPI), to identify healthy nuclei; right: cells stained with an antibody to TNF-α and with DAPI. Scale bar, 50 μm (original magnification, 20×). E-cadherin / Nanog ; PubMed: 25538040 Stem Cells hESCs were treated with either vehicle (Veh) or BIO for 6 hours. Twenty-four hours after removal of BIO, hESCs exhibit thick and compact colonies that express higher levels of E‐cadherin (E‐cad) and Nanog. Oct3/4; PubMed: 25538040 Stem Cells hESCs were treated with either vehicle (Veh) or BIO for 6 hours. Twenty‐four hours after removal of BIO, hESCs exhibit thick and compact colonies that express higher levels of E‐cadherin (E‐cad) and Oct3/4. In contrast, long-term BIO treatment leads to opposing results. Scale bar = 20 µm.	27510556 24286133 25538040
Growth inhibition assay	Cell proliferation ; PubMed: 27510556 Sci Rep The increase in cardiomyocyte proliferation after treatment with BIO for 4 days was also confirmed by MTT assay.	27510556

In vivo

BIO suppresses melanoma tumor growth in a mouse xenograft model. ^[4]

Protocol

Kinase Assay:^[1]	- Collapse Kinase assay: Kinase activities are assayed in Buffer A or C at 30°C, at a final ATP concentration of 15 μM. Blank values are subtracted and activities calculated as pmoles of phosphate incorporated during a 10 min incubation. Controls are performed with appropriate dilutions of dimethylsulfoxide. In a few cases phosphorylation of the substrate is assessed by autoradiography after SDS-PAGE. GSK-3α/β is purified from porcine brain by affinity chromatography on immobilized axin. It is assayed, following a 1/100 dilution in 1 mg BSA/ml 10 mM DTT, with 5 μl 40 μM GS-1 peptide, a specific GSK-3 substrate, (YRRAAVPPSPSLSRHSSPHQSpEDEEE), in buffer A, in the presence of 15 μM [γ-³²P] ATP (3,000 Ci/mmol; 1 mCi/ml) in a final volume of 30 μl. After 30 min incubation at 30°C, 25 μl aliquots of supernatant are spotted onto 2.5 × 3 cm pieces of Whatman P81 phosphocellulose paper, and 20 seconds later, the filters are washed five times (for at least 5 min each time) in a solution of 10 ml phosphoric acid/liter of water. The wet filters are counted in the presence of 1 ml ACS scintillation fluid.
Cell Research:^[1]	- Collapse Cell lines: COS1, Hepa or SH-SY5Y cells Concentrations: ~10 μM Incubation Time: 12 or 24 h Method: COS1, Hepa (wild-type, CEM/LM AhR deficient and ELB1 ARNT deficient), or SH-SY5Y cells are grown in 6 cm culture dishes in Dulbecco's Modified Medium (DMEM) containing 10% fetal bovine serum. For treatment, IO (5 μM), BIO (5 or 10 μM), MeBIO (5 or 50 μM), LiCl (20 or 40 mM), or mock solution (DMSO, 0.5% final concentration) is added to medium when cell density reaches ∼70% confluence. After 12 (SH-SY5Y) or 24 hours, the cells, while still in plate, are lysed with lysis buffer (1% SDS, 1 mM sodium orthovanadate, 10 mM Tris [pH 7.4]). The lysate is passed several times through a 26G needle, centrifuged at 10,000 × g for 5 min, and adjusted to equal protein concentration. About 8 μg of each sample is loaded for immunoblotting. Enhanced chemiluminescence is used for detection. The following primary antibodies are used: mouse anti-β-catenin CT (Upstate Biotechnolgies, Clone 7D8, recognizes total β-catenin), mouse anti-phospho-β-catenin (Upstate Biotechnologies, Clone 8E7, recognizes dephosphorylated β-catenin), mouse anti-GSK-3 β, mouse anti-GSK-3 phosphoTyr216, rabbit anti-AhR (Aryl hydrocarbon receptor), and rabbit anti-actin. (Only for Reference)
Animal Research:^[4]	- Collapse Animal Models: mouse Dosages: 50 mg/kg Administration: Oral gavage (Only for Reference)

References

[4] Liu L, et al. Cancer Res. 2011 Jun 1;71(11):3972-3279.

- Collapse

Solubility (25°C)

In vitro	DMSO	71 mg/mL (199.34 mM)
	Water	Insoluble
	Ethanol	'6 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50%ddH2O For best results, use promptly after mixing.	3 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BIO SDF

Molecular Weight	356.17
Formula	C₁₆H₁₀BrN₃O₂
CAS No.	667463-62-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052
Smiles	C1=CC=C2C(=C1)C(=C(N2)C3=C(NC4=C3C=CC(=C4)Br)O)N=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04263519	Not yet recruiting	Drug: Tacrolimus	Alzheimer Disease\|Mild Cognitive Impairment	Massachusetts General Hospital	December 1 2021	Phase 2
NCT04889183	Not yet recruiting	Drug: Semaglutide\|Drug: Placebo	Obesity\|Albuminuria	University Medical Center Groningen\|Novo Nordisk A/S	September 2021	Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

GSK-3 Signaling Pathway Map

Related GSK-3 Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
LY2090314 ^New

LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 is highly selective towards GSK3 as demonstrated by its fold selectivity relative to a large panel of kinases.
TDZD-8 ^New

TDZD-8 (NP 01139) is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
TWS119

TWS119 is a GSK-3β inhibitor with IC50 of 30 nM in a cell-free assay; capable of inducing neuronal differentiation and may be useful to stem cell biology. GSK-3β inhibition triggers autophagy.
SB216763

SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β. SB216763 activates autophagy.
Tideglusib (NP031112)

Tideglusib (NP031112, NP-12) is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2.
CHIR-98014

CHIR-98014 (CT98014) is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.
AR-A014418

AR-A014418 (GSK-3β Inhibitor VIII) is an ATP-competitive, and selective GSK3β inhibitor with IC50 and K_i of 104 nM and 38 nM in cell-free assays, without significant inhibition on 26 other kinases tested.

Choose Your Country or Region

By Signaling Pathways

By product type

BIO